337 related articles for article (PubMed ID: 26643807)
21. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CS; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; ; Rosenthal MA
Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Peters KB; Lipp ES; Miller E; Herndon JE; McSherry F; Desjardins A; Reardon DA; Friedman HS
J Neurooncol; 2018 Apr; 137(2):349-356. PubMed ID: 29264836
[TBL] [Abstract][Full Text] [Related]
23. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
Chen W; Delaloye S; Silverman DH; Geist C; Czernin J; Sayre J; Satyamurthy N; Pope W; Lai A; Phelps ME; Cloughesy T
J Clin Oncol; 2007 Oct; 25(30):4714-21. PubMed ID: 17947718
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.
Drappatz J; Lee EQ; Hammond S; Grimm SA; Norden AD; Beroukhim R; Gerard M; Schiff D; Chi AS; Batchelor TT; Doherty LM; Ciampa AS; Lafrankie DC; Ruland S; Snodgrass SM; Raizer JJ; Wen PY
J Neurooncol; 2012 Mar; 107(1):133-8. PubMed ID: 21984064
[TBL] [Abstract][Full Text] [Related]
25. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
Gururangan S; Chi SN; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Friedman HS; Packer RJ; Rood BN; Boyett JM; Kun LE
J Clin Oncol; 2010 Jun; 28(18):3069-75. PubMed ID: 20479404
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
27. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.
Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Sampson JH; Sathornsumetee S; McLendon RE; Herndon JE; Marcello JE; Norfleet J; Friedman AH; Bigner DD; Friedman HS
Br J Cancer; 2009 Dec; 101(12):1986-94. PubMed ID: 19920819
[TBL] [Abstract][Full Text] [Related]
28. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
29. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN).
DeWire M; Fouladi M; Turner DC; Wetmore C; Hawkins C; Jacobs C; Yuan Y; Liu D; Goldman S; Fisher P; Rytting M; Bouffet E; Khakoo Y; Hwang EI; Foreman N; Stewart CF; Gilbert MR; Gilbertson R; Gajjar A
J Neurooncol; 2015 May; 123(1):85-91. PubMed ID: 25859842
[TBL] [Abstract][Full Text] [Related]
30. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY
Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329
[TBL] [Abstract][Full Text] [Related]
33. A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.
Odia Y; Sul J; Shih JH; Kreisl TN; Butman JA; Iwamoto FM; Fine HA
CNS Oncol; 2016; 5(2):59-67. PubMed ID: 26860632
[TBL] [Abstract][Full Text] [Related]
34. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.
Raizer JJ; Grimm S; Chamberlain MC; Nicholas MK; Chandler JP; Muro K; Dubner S; Rademaker AW; Renfrow J; Bredel M
Cancer; 2010 Nov; 116(22):5297-305. PubMed ID: 20665891
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
Raymond E; Brandes AA; Dittrich C; Fumoleau P; Coudert B; Clement PM; Frenay M; Rampling R; Stupp R; Kros JM; Heinrich MC; Gorlia T; Lacombe D; van den Bent MJ;
J Clin Oncol; 2008 Oct; 26(28):4659-65. PubMed ID: 18824712
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.
Poulsen HS; Grunnet K; Sorensen M; Olsen P; Hasselbalch B; Nelausen K; Kosteljanetz M; Lassen U
Acta Oncol; 2009; 48(1):52-8. PubMed ID: 19031176
[TBL] [Abstract][Full Text] [Related]
37. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
Galanis E; Anderson SK; Twohy EL; Carrero XW; Dixon JG; Tran DD; Jeyapalan SA; Anderson DM; Kaufmann TJ; Feathers RW; Giannini C; Buckner JC; Anastasiadis PZ; Schiff D
Cancer; 2019 Nov; 125(21):3790-3800. PubMed ID: 31290996
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics.
Nwankwo N; Zhang Z; Wang T; Collins C; Resta L; Ermisch S; Day J; Decker R; Kornberg L; Nicol S; Thornton D; Armstrong DK; Carducci MA
Invest New Drugs; 2013 Jun; 31(3):653-60. PubMed ID: 22766773
[TBL] [Abstract][Full Text] [Related]
39. Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.
Nagpal S; Recht CK; Bertrand S; Thomas RP; Ajlan A; Pena J; Gershon M; Coffey G; Kunz PL; Li G; Recht LD
J Neurooncol; 2015 Jun; 123(2):277-82. PubMed ID: 25935109
[TBL] [Abstract][Full Text] [Related]
40. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.
Quant EC; Norden AD; Drappatz J; Muzikansky A; Doherty L; Lafrankie D; Ciampa A; Kesari S; Wen PY
Neuro Oncol; 2009 Oct; 11(5):550-5. PubMed ID: 19332770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
